Skip to Main Content

Was the FDA right to approve Aduhelm? What’s a fair price for a debatable drug? And what does this have to do with ’80s HIV activism?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We’re devoting this entire episode to the FDA’s polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer’s disease. First, we’ll break down what happened and why it’s such a big deal, and then we’ll talk about the broader implications for science, medicine, and the drug industry as a whole. Finally, we’ll zoom out explore how the FDA got to this moment in a conversation with Yale University professor and global health activist Gregg Gonsalves.

For more on what we cover, here’s the approval news; here’s more on the implications for the FDA; here’s the story on Aduhelm’s price; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.


Be sure to sign up on Apple PodcastsStitcherGoogle Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].

Create a display name to comment

This name will appear with your comment